InvesTrust Sells 540 Shares of Eli Lilly and Company (NYSE:LLY)

InvesTrust trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,841 shares of the company's stock after selling 540 shares during the quarter. Eli Lilly and Company accounts for approximately 2.4% of InvesTrust's investment portfolio, making the stock its 7th largest position. InvesTrust's holdings in Eli Lilly and Company were worth $8,954,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Knightsbridge Asset Management LLC grew its holdings in shares of Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares during the last quarter. Centerpoint Advisory Group bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $514,000. Kentucky Trust Co bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $834,000. CSM Advisors LLC grew its holdings in shares of Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after purchasing an additional 245 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its holdings in shares of Eli Lilly and Company by 30.2% in the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock worth $5,202,000 after purchasing an additional 1,562 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Up 2.1%

Shares of LLY traded up $16.00 during mid-day trading on Wednesday, hitting $766.78. 3,131,770 shares of the company traded hands, compared to its average volume of 3,637,015. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $726.71 billion, a PE ratio of 65.48, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The business has a 50 day moving average of $773.82 and a 200 day moving average of $799.64.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the company earned $2.58 EPS. The business's revenue was up 45.2% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, May 30th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.